Related Experiment Video
Updated: Jul 21, 2025
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.3K
Should Prediabetes be Treated Pharmacologically?
1Charles R. Drew University, 1731 East 120th Street, Los Angeles, CA, 90059, USA. mayerdavidson@cdrewu.edu.
Summary
Pharmacological treatment for prediabetes is not recommended. However, weight loss achieved with GLP-1 receptor agonists or dual agonists shows promise for improving insulin resistance and reducing diabetes risk.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Pharmacology
Background:
- Prediabetes lacks independent cardiovascular risk; metabolic syndrome factors drive risk.
- Diagnostic criteria vary, leading to prevalence estimates from 6% to 38%.
- Many individuals with prediabetes spontaneously recover or do not progress to diabetes.
Purpose of the Study:
- To evaluate the pharmacological treatment of prediabetes.
- To assess the efficacy of current medications in addressing underlying pathophysiology.
- To explore alternative therapeutic strategies for prediabetes management.
Main Methods:
- Review of existing literature on prediabetes diagnosis and treatment.
- Analysis of pharmacological interventions and their long-term effects.
- Consideration of weight-loss interventions and their impact on insulin resistance.
Main Results:
- Pharmacological treatment of dysglycemia in prediabetes is not supported by current evidence.
- Discontinuation of glucose-lowering drugs does not alter insulin resistance or secretion.
- Weight loss of 15-20% via GLP-1 receptor agonists or dual agonists shows potential.
Conclusions:
- Pharmacological management of prediabetes dysglycemia is not warranted.
- High-dose GLP-1 receptor agonists and dual GIP/GLP-1 agonists offer significant weight reduction, a promising therapeutic avenue.
- Achieved weight loss can improve insulin resistance and endogenous insulin effectiveness, potentially lowering diabetes incidence.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
317
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
317
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
01:23Dipeptidyl Peptidase 4 Inhibitors
212
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
208
01:06Oral Hypoglycemic Agents: Glinides
188
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
188
01:22Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K